Aditxt Inc. (ADTX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
ADTX Chart
Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 30, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that, in response to the notice received from Aditxt Inc. (“Aditxt”) on May 17, 2025, the Company has delivered formal notice to Aditxt to terminate the arrangement agreement (the “Arrangement Agreement”) dated April 1, 2024 (as amended) between the Company, Aditxt and its wholly-owned subsidiary, Adivir, Inc. (“Adivir”). Such termination is effective as of May 30, 2025.
Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 19, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, announced that Aditxt, Inc. (“NASDAQ:ADTX”) (“Aditxt”) has delivered notice (the “Termination Notice”) purporting to terminate the arrangement agreement dated April 1, 2024 between the Company, Aditxt, and its wholly-owned subsidiary, Adivir, Inc. (“Adivir”) (as amended on July 1, 2024 and further amended on July 17, 2024 and as further amended on August 20, 2024, the “Arrangement Agreement”), such termination to be effective as of May 31, 2025. Under the Arrangement Agreement, the Company is entitled to a termination fee (the “Termination Fee”) in the amount of USD$1,250,000 payable by Aditxt upon termination of the Arrangement Agreement in certain circumstances.
Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
Event exploring the escalating threat of emerging infectious diseases Discussion covering going-private transaction with Aditxt, strategic growth partner HALIFAX, Nova Scotia, April 02, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that its President and CEO, Don Cilla, Pharm.D., M.B.A., will join Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt") Co-founder and CEO, Amro Albanna, for the Aditxt Weekly Update on April 4, 2025.
Aditxt Inc. Dividends
Aditxt Inc. Earnings
| 19 May 2025 Date | | - Cons. EPS | - EPS |
| 12 Nov 2024 Date | | - Cons. EPS | - EPS |
| 19 Aug 2024 Date | | - Cons. EPS | - EPS |
| 15 Aug 2024 Date | | - Cons. EPS | - EPS |
| 16 Apr 2024 Date | | - Cons. EPS | - EPS |
| 19 May 2025 Date | | - Cons. EPS | - EPS |
| 12 Nov 2024 Date | | - Cons. EPS | - EPS |
| 19 Aug 2024 Date | | - Cons. EPS | - EPS |
| 15 Aug 2024 Date | | - Cons. EPS | - EPS |
| 16 Apr 2024 Date | | - Cons. EPS | - EPS |
Aditxt Inc. (ADTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Aditxt Inc. ever had a stock split?
Aditxt Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Amro A. Albanna CEO | NASDAQ (CM) Exchange | 007025109 Cusip |
| US Country | 26 Employees | - Last Dividend | 17 Mar 2025 Last Split | 30 Jun 2020 IPO Date |
Overview
Aditxt, Inc. is a biotech entity that has dedicated its efforts to the innovation and commercialization of advanced technologies aimed at enhancing health by closely monitoring and effectively modulating immune system functionalities. Initially founded under the name ADiTx Therapeutics, Inc., the corporation underwent a rebranding to Aditxt, Inc. in July 2021, marking a new chapter in its mission towards immune health. With its foundation dating back to 2017 and its central operations based in Richmond, Virginia, Aditxt has not only established itself in the biotechnological landscape but also has solidified collaborative ties, through license agreements, with prestigious institutions like Loma Linda University and Leland Stanford Junior University. These collaborations underscore the company's commitment to pioneering immune modulation and monitoring methodologies for public health betterment.
Products and Services
- AditxtScore
- Apoptotic DNA Immunotherapy
- ADI-100
This innovation represents a cornerstone in personal health empowerment, enabling individuals to extensively comprehend, efficaciously manage, and consistently monitor their immune profile. Through this, it provides insights into potential assaults by or against the immune system, equipping individuals with actionable data to fortify their health.
Aditxt is pioneering in the arena of nucleic acid-based technologies with its Apoptotic DNA Immunotherapy. This cutting-edge approach mirrors the body’s natural mechanisms of inducing tolerance towards its tissues. It epitomizes a significant leap forward in how autoimmune diseases and disorders are approached, potentially offering novel avenues for therapy and patient care.
ADI-100 emerges as a promising therapeutic candidate under Aditxt’s development pipeline aimed at addressing several critical health conditions inclusive of skin grafting challenges, psoriasis, type 1 diabetes, and multiple sclerosis. This breadth of application signifies the potential of ADI-100 to revolutionize treatment paradigms across diverse medical fields.
Contact Information
